Amgen stock: buy or sell
Updated on:
Jan 16th, 2021
2
Amgen stock brief
- Counting on Friday, it's been 3 consecutive sessions in positive for Amgen. Price closed on Friday at $245.49 after rising a 1.58%.
- On Friday, it broke out above $244.18, a resistance not crossed since last November.
- The price is currently above the upper Bollinger band, which is usually an indicator of a near-term correction
- Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Should I buy Amgen stock?
Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best
Is $AMGN stock a buy?
In the current situation of Amgen there is not any eligible buy setup. This doesn't mean we expect a selloff for $AMGN in coming sessions, or that it may not rise higher. Simply, it doesn't match our recommended trading systems
Should I sell Amgen stock?
When is it time to sell Amgen?. Trading strategies prevent us from making impulsive decisions based on our moods or the buzz that surrounds the market. When selling, as well as buying, our setups are very simple to follow but are only applicable for selling stocks in your porfolio, not for selling short Amgen stock
A guiding principle is that you must never keep an operation that results in greater losses than those expected by the time of the buy. The timing to sell shares always has to be ruled by the stop-loss (automatic or manual)
Is it time to sell Amgen stock?
Currently, Amgen stock doesn't match any of our preferred sell setups, so if you hold Amgen stock and your operation is in profit probably is not time to sell now
Amgen ratings
In the last 30 days, 5 analyst ratings were published for Amgen
| Brokerage firm | Rating |
|---|---|
| Dec 23rd, 2020 | |
| Royal Bank of Canada | Neutral |
| Dec 27th, 2020 | |
| JPMorgan Chase & Co. | Neutral |
| Dec 29th, 2020 | |
| Daiwa Capital Markets | |
| Royal Bank of Canada | Neutral |
| Jan 4th, 2021 | |
| Royal Bank of Canada | Neutral |
Amgen stock analysis
SMAs overview
Supports and resistances
The current resistance levels are:
The current support levels are:
Bollinger bands
Price readings above or below the Bollinger Bands signal that the price has followed a strong trend that has led to extreme highs or lows. For this case, the price is beyond the upper band, meaning a possible short-term adjustment (at least) until it is below the band
Relative strength index
Crossed over the 70 level Friday, with a value of 71.38. Breaking through above the overbought zone is not a bearish signal, as stock price can be above 70 for many, many weeks and continue to rise
Amgen stock price history
Amgen went public priced at an adjusted price1 of $0.00 on Jun 1983. Since then, AMGN stock surged by -, with an average of 0.00% per year. If you had invested $1,000USD in Amgen stock on the IPO, it would be valued $inf today.
1: Adjusted price after possible price splits or reverse-splits
Price target for Amgen stock
How much a stock will be priced tomorrow or next week is quite unpredictable. Banks and financial organisations issue their analysis predicting how a particular stock will performance in the future.
Along with buy or sell recommendations, financial institutions publish their price target based on the stock price action and the company fundamental data. Most of these predictions follow the publication of new fundamental data by the company, and usually. If you are a small investor you must not invest based on these projections.
There is just one price target available for Amgen that predicts a price of $300.00.
| Brokerage firm | Price target |
|---|---|
| Dec 23rd, 2020 | |
| Royal Bank of Canada | Not available |
| Dec 27th, 2020 | |
| JPMorgan Chase & Co. | Not available |
| Dec 29th, 2020 | |
| Daiwa Capital Markets | $300.00 → $300.00 |
| Royal Bank of Canada | Not available |
| Jan 4th, 2021 | |
| Royal Bank of Canada | Not available |
Earnings and financials
Amgen Inc. ($AMGN) posted earnings of $4.37 per share last October, uplifting the analysts consensus estimate of $3.80 per share. This quarterly report represents an earnings surprise of 15.00%. On the contrary, the company said revenue was $6.4 billion consistent with analysts' estimates.
For comparison, the EPS for the same quarter last year was $3.66, so posted EPS means a improvement of 19.40%. Sales grew a 11.96% on an annualized basis in the , from $57.4B to $64.2B last quarter.Amgen ($AMGN) will host the earnings call on January 28. Expected for this quarter is $3.41, compared to $4.37 that was reported for Q3.
Amgen performance
| Company | 1m | 3m | 6m |
|---|---|---|---|
| Amgen ($AMGN) | 6.70% | 5.00% | -4.30% |
Please read:
The thoughts contained in this article are personal and should not be followed as recommendations for you to buy or sell stocks. The author of this article does not have an understanding of the specific circumstances of the reader, his or her finances or his or her own best interests at any given time. All users should speak with their financial advisor before buying or selling any securities Thoughts are expressed for general educational purposes onlyAmgen summary
| Friday, January 15th, 2021 | |
|---|---|
| Open | $241.18 |
| Close | $245.49 |
| Day range | $240.02 - $246.84 |
| Previous close | $241.66 |
| Session gain | 1.58% |
| Average true range | $5.85 |
| 50d mov avg | $229.42 |
| 100d mov avg | $234.51 |
| 200d mov avg | $233.46 |
| Earnings date | January 28th, 2021 |